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The life cycle of papillomaviruses is tightly linked to differentiation of host keratinocytes, but the mechanisms and cues by which life cycle
events are tied to differentiation remain obscure. We have begun a systematic study of the differentiation-dependent life cycle of HPV31. A variety
of signaling pathways have been implicated in controlling keratinocyte differentiation, especially the protein kinase C (PKC) pathway. We have
used pharmacological inhibitors to determine that genome amplification and late transcription depend on specific PKC isoforms, and that
transcription and replication are independently controlled. We found that tyrosine kinases are necessary for viral amplification but not viral
transcription. These studies indicate that the PKC pathway is an important regulator of differentiation-dependent HPV31 replication and
transcription.
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Human papillomaviruses are small closed-circular DNA
viruses that infect the keratinocytes of stratified squamous
epithelia, causing benign or malignant hyperproliferative
lesions (zur Hausen, 1991, 1996). Over 100 types of
papillomaviruses have been identified to date, infecting
numerous cutaneous or mucosal sites with strong species and
tissue tropism (zur Hausen, 1999). Because of their association
with malignancies including cervical cancer, certain mucosal
HPV types, such as 16, 18, and 31, are of particular medical
concern. HPVs are thought to gain access to the basal cells of
the epithelium through small traumas (Pfister, 1990). After a
burst of DNA replication to establish a copy number of 50–200
in basal cells, the virus maintains itself in the basal layer
replicating on average once per cell cycle as an episome (Flores
and Lambert, 1997). The major early promoter (p99 in HPV31)
drives most viral transcription in this layer (Ozbun and Meyers,⁎ Corresponding author. Fax: +1 717 531 4600.
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doi:10.1016/j.virol.2006.01.0361998b). As the cells move from the basal into the spinous layer
of the epithelium, the first step in the keratinocyte differenti-
ation program, the intermediate phase of the viral life cycle
begins. The viral late promoter (p742 in HPV31) is activated,
and the viral genome amplifies to thousands of copies per cell
(Flores and Lambert, 1997; Ruesch et al., 1998). This is
accompanied by an increase in transcripts for the intermediate
genes, E1, E2, and E1^E4 (Ozbun and Meyers, 1997, 1998a).
As infected cells undergo terminal differentiation in the granular
and cornified layers, viral late genes, including the major and
minor capsid proteins L1 and L2, are expressed and virions are
assembled (Meyers et al., 1992).
Cellular differentiation controls or influences at some level
every known step of the viral life cycle including productive
genome replication (Bedell et al., 1991; Flores and Lambert,
1997), transcription (Hummel et al., 1992; Ozbun and Meyers,
1998b; Ruesch et al., 1998), splicing (Barksdale and Baker,
1995; Ozbun and Meyers, 1997), polyadenylation (Baker and
Noe, 1989; Terhune et al., 1999, 2001), translation (Cumming et
al., 2003; Koffa et al., 2000; McPhillips et al., 2004), virion
morphogenesis (Meyers et al., 1992, 1997), and release by
desquamation (Bryan and Brown, 2001). Arguably, even the
well-studied oncogenes, whose major functions are to induce
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the virus delays replication until the cells are differentiated.
Keratinocyte differentiation is directed by the interplay and
coordination of a variety of signaling pathways (Fig. 1), many
of which are still poorly understood, that appear to be activated
in an orderly manner as keratinocytes move through the stages
of maturation (Dotto, 1999; Eckert et al., 1997a, 1997b). How
HPV senses, responds to, and manipulates the complex
signaling environment of a differentiating keratinocyte is not
known. Transcription factors regulated by differentiation,
including AP-1, CDP, C/EBP, and Skn-1a (Ai et al., 1999;
Andersen et al., 1997; Kyo et al., 1995; Sen et al., 2004) are
known to regulate gene expression from the viral early
promoter. However, the signaling pathways that are responsible
for controlling HPV behavior in differentiating cells are not well
understood.
Protein kinase C (PKC) is a family of signaling enzymes
especially important in differentiation, and the different PKC
isoforms expressed in keratinocytes appear to have distinct
functions in the keratinocyte differentiation program (Denning
et al., 1995b; Dlugosz and Yuspa, 1993; Ohba et al., 1998; Papp
et al., 2003; Seo et al., 2004; Yang et al., 2003). The upstream
regulatory region (URR) of HPV16 can be activated by the PKC
agonist TPA (Chan et al., 1990), and AP-1, which is a well-
characterized factor downstream of PKC, has been shown to be
critical for HPVearly promoter activity (Bouallaga et al., 2000;
Kyo et al., 1997; Thierry et al., 1992), although the activity of
the early promoter does not change during differentiationFig. 1. Signaling pathways in keratinocytes. Drugs used in this stud(Ozbun and Meyers, 1998b). PKC activation is necessary for
the efficient completion of the late phase of the HPV life cycle
in vitro (Meyers et al., 1992), probably by regulating the
expression of late genes via post-transcriptional mechanisms
(Hummel et al., 1995; Terhune et al., 1999). We have found that
HPV31 genome amplification in the intermediate phase of the
life cycle depends on PKC activity (Bodily and Meyers, 2005).
Given the lack of information about the cues in a
differentiating cell that control the HPV life cycle, we sought
to better understand the role of PKC in regulating HPV31
genome amplification and p742 activation upon differentiation.
We found evidence that PKCδ is involved in p742 activation,
and that genome amplification requires PKCδ, α, and tyrosine
phosphorylation. We also confirmed and extended our previous
observation that viral genome amplification is not necessary for
p742 activation (Bodily and Meyers, 2005).
Results
Cells harboring episomally replicating HPV31 were treated
with drugs and cultured under two different conditions: in
monolayer culture, which models the undifferentiated basal
layer of the stratified epithelium, and suspension in medium
containing 1.6% methylcellulose (MC), which induces differ-
entiation of cells at least to the spinous level and triggers both
amplification of the viral genome and activation of the late
promoter, p742 (Ruesch et al., 1998). We used two cell lines in
these studies: CIN-612 9E cells (9E), which were derived fromy are indicated at their points of action in bold and italic type.
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1991; Rader et al., 1990), and HFK31a:1 cells (WT:1), which
were derived in the laboratory by electroporation of primary
human foreskin keratinocytes with wild-type HPV31 genomic
DNA and also maintain the HPV31 genome episomally (Bodily
and Meyers, 2005).
The effect of protein kinase C inhibition on viral behavior
Because of the importance of PKC in keratinocyte differen-
tiation (Denning et al., 1995a; Lee et al., 1997; Szallasi et al.,
1995; Yang et al., 2003) and because of existing evidence
implicating PKC to various aspects of the HPV life cycle (Bodily
and Meyers, 2005; Hummel et al., 1995; Meyers et al., 1992;
Terhune et al., 1999), we chose to test whether this family of
enzymes is necessary for late promoter activation and genome
amplification. Bisindolylmaleimide I, or GF109203× (GF), is a
derivative of staurosporine that is specific for PKC, with IC50
values at least an order of magnitude lower than phosphorylase
kinase, the next most inhibited enzyme tested (Toullec et al.,
1991). GF inhibits all isoforms of PKC by binding the ATP
binding site and is biologically active and nontoxic at
concentrations around 1–5 μM (Toullec et al., 1991). This
inhibitor has become somewhat standard in studies of PKC and
keratinocyte differentiation (Denning et al., 1995b; Dlugosz
and Yuspa, 1994; Stanwell et al., 1996; Tibudan et al., 2002).
As reported earlier (Bodily and Meyers, 2005), GF at 5 μM
could block amplification of the HPV31 genome in 9E cells
while failing to block activation of p742, providing evidence that
p742 does not require amplification and that amplification
requires PKC. Given this interesting observation, we thought it
worthwhile to further investigate GF and its activities.
GF has been reported to block cell cycle withdrawal and
expression of involucrin in primary human foreskin keratino-
cytes placed in suspension (Tibudan et al., 2002). We therefore
wished to determine whether GF is able to block expression of
this early differentiation marker in 9E cells suspended in MC
culture. As shown in Fig. 2a, suspension of 9E cells in MC
increased involucrin expression, but this increase was not
observed in cultures treated with 5 or 10 μM GF. Note that the
involucrin expression seen in monolayer culture, which isFig. 2. The efficacy of GF in inhibiting involucrin expression and PKCα
activity. 9E cells were cultured in monolayer or suspended in MC for 2 days in
the presence of the indicated concentrations of GF. Whole cell extracts were
prepared and (a) immunoblotted using an antibody against involucrin (arrow) or
(b) tested for PKCα kinase activity using histone H1 as a substrate (arrow).consistent with a low level of differentiation being present in
monolayer cultures (Ozbun and Meyers, 1997), was also
reduced by GF treatment. GF treatment had no effect on the
expression of K14, a marker of the basal layer (data not shown).
GF also had no obvious effects on the growth or morphology of
cells in monolayer culture at 5 or 10 μM, although at 25 μM, the
cells were somewhat spindly (data not shown). To more directly
test the efficacy of GF as an inhibitor of PKC activity, we
performed a kinase assay for PKCα, one of the PKC isoforms
present in skin (Deucher et al., 2002), using extracts of GF-
treated or untreated 9E cells grown in monolayer or MC culture.
As seen in Fig. 2b, GF was able to inhibit the kinase activity of
PKCα in both monolayer and MC.
In a previous study, 5 μMGF failed to block p742 activation
in MC in 9E cells (Bodily and Meyers, 2005). In order to
determine whether this effect was specific for 9E cells, we
treated WT:1 cells with several concentrations of GF and
measured the response of p742 and viral genome replication.
Amplification of the viral genome measured by Southern
blotting was clearly inhibited by GF at 5 and 10 μM, as in 9E
cells (Fig. 3a; Bodily and Meyers, 2005). Although p742
transcript levels measured by ribonuclease protection assay
(RPA) were not reduced to the level seen in monolayer at either
dose tested, GF was able to reduce p742 activity to significantly
below that seen in untreated cells in MC (Fig. 3b). Inhibition of
p742 activation was also seen at 10 μMGF in 9E cells (data not
shown). Thus, rather than being completely insensitive to GF as
we previously thought, p742 seems to require PKC at some
level, but p742 has a different dose response to GF as compared
to amplification, consistent with the biochemical separation seen
in our earlier experiments (Bodily and Meyers, 2005). It should
be noted that there was some variability from experiment to
experiment in the particular dose at which GF inhibited p742
activation and between cell lines. However, GF consistently
inhibited amplification at every dose tested, and the fairly high
dose of 10 μM GF was usually sufficient to inhibit p742. Some
variability between 9E and WT:1 cells may be attributable to
differing host factors. 25 μM GF was toxic for both cell lines
(data not shown).
In order to map the potential GF-repressible transcriptional
element(s) in p742, we transfected several luciferase reporter
plasmids into 9E cells and cultured the cells in MC, with or
without 5 μM GF. The luciferase activities for each construct
were measured, and the ratios of “with GF” vs. “without GF”
treatment are shown in Fig. 3c. Fragment A, which includes the
viral upstream regulatory region (URR), major enhancer
elements, and both the early (p99) and late promoters, was
repressed by GF about 50%, as was fragment H, which contains
the late promoter p742 and flanking differentiation response
elements. The fragment A reporter with a mutation in the TATA
box of the early promoter p99 was repressed more than the wild-
type fragment A, suggesting that p99 may serve to counteract
the loss of activity seen with GF treatment of wild type.
Fragment T, which contains the core promoter for p742 but is
not activated by differentiation (Bodily and Meyers, 2005), was
completely resistant to GF treatment at this concentration.
Therefore, the transcriptional elements that are repressible by
Fig. 3. The effect of GF on amplification, p742, and reporter expression. WT:1 cells were cultured in monolayer or in MCwith 0, 5, or 10 μMGF analyzed by Southern
blot for HPV31 DNA (a) or by RPA using a probe specific for p742 (b). B, digested with BamHI, which does not cut the HPV31 genome; H, digested with HindIII
which digests the HPV31 genome once; Y+, yeast RNAwith RNAse treatment; Y−, yeast RNAwithout RNAse treatment. In panel (b), a probe against the cellular
cyclophilin transcript was included as an internal control. (c) The indicated reporter constructs were transfected into 9E cells and then incubated with 0 or 5 μMGF in
MC culture. The ratio of +GF to −GF was measured for each construct and averaged between experiments. Bars represent ±1 standard error of the mean.
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nucleotides 231–530 or downstream of nucleotide 680.
Interestingly, these are the same regions we previously mapped
as being important for activation of p742 by differentiation
(Bodily and Meyers, 2005), supporting our hypothesis that the
PKC pathway contributes to the ability of p742 to respond to
differentiation.
The effect of GF on the intermediate transcripts and p99
Since p742 and amplification were both effectively blocked
by GF in WT:1 cells, we wished to establish a lower
concentration limit for this effect and to determine whether
transcripts driven by p742 are also inhibited by GF. Treating
WT:1 cells in MC with a range of GF concentrations, we found
an inhibitory effect of GF as low as 0.5 μM (Fig. 4a). We
expected that the intermediate transcript unit, which is
immediately downstream of p742 and contains the viral
replication factors E1, E2, and E4, would also be blocked by
GF. Surprisingly, this was not the case, as seen in Fig. 4b, as the
intensity of the E1, E2, and E4 bands were unchanged at any of
the tested concentrations of GF. Note that the RNA samples
analyzed in the RPA in Fig. 4b were the same samples analyzed
for p742 activity in Fig. 4a in which a reduction of band
intensity was seen at all concentrations. This finding was
surprising given that we have assumed p742 to be the principalregulator of the levels of these transcripts. Having noticed that
mutation of the p99 TATA box seemed to accentuate inhibition
of fragment A activity by GF (Fig. 3c), we wished to determine
whether p99 is activated by GF. p99 transcripts in 9E cells
treated with 5 μM GF and cultured in MC were increased by
about 2.5-fold (Fig. 4c). Note that p99 transcript levels are not
altered by differentiation in untreated cultures, consistent with
previous studies (Ozbun and Meyers, 1998b; Sen et al., 2002).
In summary, we have observed that inhibition of the PKC
signaling family with GF was able to inhibit p742 and activate
p99. Despite these changes in promoter activities, however, the
levels of intermediate transcripts were not affected by GF
treatment at the concentrations tested. These observations
suggest that there may be a reciprocal or coordinated response
mechanism regulating these two HPV promoters.
Inhibition of specific PKC isoforms
Finding that inhibiting PKC could block amplification and
p742 activation (Figs. 3 and 4), we sought to determine which
PKC isoform(s) were responsible. Keratinocytes express five
PKC isoforms: PKCα, δ, ε, η, and ζ (Deucher et al., 2002;
Dlugosz et al., 1992). Of these, PKCα, δ, and η are most often
implicated in regulation of differentiation (Denning et al.,
1995a; Deucher et al., 2002; Ohba et al., 1998; Seo et al., 2004;
Tibudan et al., 2002). Of these three, small molecule inhibitors
Fig. 4. The effect of GF on p99 and intermediate transcript expression. WT:1 (a and b) or 9E (c) cells were treated with the indicated concentrations of GF in monolayer
or MC culture. Total RNAs were analyzed by RPA using a probe against (a) p742, (b) a mixture of probes against E1, E2, and the ^E4 splice junction, or (c) p99. A
probe against cyclophilin was included in each reaction as an internal control. Beneath the RPA in part (c) is a densitometric analysis of the p99 bands from two
independent experiments. p99 densitometry values were normalized to the cyclophilin control within each reaction, divided by the untreated monolayer value for each
experiment, and averaged between experiments. Also shown is ±1 standard error of the mean. Y+, yeast RNAwith RNAse treatment; Y−, yeast RNAwithout RNAse
treatment.
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(Rott) for PKCδ. Like GF, these inhibitors have been used in
several published studies of PKC isoforms in keratinocytes
(Deucher et al., 2002; Efimova and Eckert, 2000; Tibudan et al.,
2002). Therefore, we treated 9E and WT:1 cells with these two
compounds and examined their effects on HPV replication and
promoter activation. There were no obvious effects of these
agents on growth or morphology of cells in monolayer culture
after 48 h in any of our experiments (not shown). Both Rott and
Gö, like GF, were able to prevent amplification of HPV31
genomes in WT:1 cells MC (Fig. 5a). Since the level of viral
DNA was lower in treated MC cultures than in monolayer,
PKCα and/or δ activity may also contribute to episomal
maintenance. Similar results were seen with 9E cells (not
shown). Treatment of cells with Hispidin, which inhibits the β
isoform of PKC, which is not expressed in keratinocytes, had no
effect on amplification (data not shown). We conclude from
these data that activities of both PKCα and δ are needed for
amplification to occur.
Using RPA analysis on RNAs from treated cells, we found
that Rott modestly but consistently reduced p742 activation in
MC in both 9Es and WT:1 cells (Fig. 5b and data not shown).
This suggests that the PKCδ isoform is needed for p742
activation. Note that the DNA analyzed in Fig. 5a and the RNA
analyzed in Fig. 5b were from the same cultures. Thus, the fact
that Gö could effectively block amplification and not p742
activation in the same culture illustrates that these two events
can be separated, as we have shown before (Bodily and Meyers,
2005). Like p742 activation, intermediate transcript expression
was reduced by Rott but not Gö (Fig. 5c). However, neither
p742 nor intermediate transcript expression was reduced to thelevel of monolayer in WT:1 cells, suggesting that dependence
on PKCδ may not be complete.
The effects of inhibitory drugs on organotypic raft cultures
Experiments discussed so far using PKC inhibitors employed
48 h of culture in MC as a model of differentiation. We wished
to determine the effect of these agents on organotypic raft
cultures, which sustain a more complete differentiation program
and a longer time course. Raft cultures of 9E and WT:1 cells
were constructed and treated for 10 days with GF, Rott, and Gö,
each at 5 μM, or with C8 at 10 μM. Hematoxylin and eosin
sections of 9E rafts treated for 10 days are shown in Fig. 6;
effects on WT:1 rafts were similar (not shown). It was noted at
harvest that GF-treated rafts were tougher in texture than
controls. This difference was not reflected in any obvious
characteristics at the morphological level, except for a slight
increase in the number of large cells in the spinous and granular
layers (Fig. 6b). We noted that at 5 days of culture, GF-treated
rafts were thicker and more stratified than rafts treated with E
medium alone (not shown), and that primary human foreskin
keratinocyte rafts treated with GF were also thicker and more
stratified than controls at 10 days (not shown). That stratifica-
tion could still occur in the face of PKC inhibition was
surprising, given the reported importance of PKC in differen-
tiation induced in other cell culture models (Denning et al.,
1995b; Ohba et al., 1998; Seo et al., 2004; Yang et al., 2003).
DMSO had no negative effect on differentiation of either cell
line but if anything tended to increase the amount of
stratification and cornification slightly in multiple images.
The effect of Gö on growth and stratification of raft cultures was
Fig. 5. Effects of PKC isoform inhibitors and genestein on replication, p742, and intermediate transcript expression. WT:1 cells were incubated for 2 days in monolayer
or MC in the presence of the indicated drugs, each at 5 μM. Cells were harvested and examined by Southern blotting (a) for the level of viral replication. B, digested
with BamHI, which does not cut the HPV31 genome; H, digested with HindIII which digests the HPV31 genome once. RPA analyses on total RNAs were performed
using probes specific for p742 (b) or a mixture (c) of probes against E1 and E2/^E4. A probe against cyclophilin was included as an internal control. Y+, yeast RNA
with RNAse treatment; Y−, yeast RNA without RNAse treatment.
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layers but the growth was patchy over the surface of the raft,
with large areas having no growth at all. In rafts treated with
Rott, large holes were seen in the tissue, some of which were
bigger than whole cells, giving the tissue a “frothy” appearance
(Fig. 6g). The basis of this interesting response is unknown, but
treatment for 5 days followed by 5 days of chase with E medium
alone suggested that a normal basal layer could be regenerated
to some extent (data not shown). It was curious that inhibiting
either PKCα or δ alone should have such a profound effect on
morphology but blocking all PKCs with GF did not (compare
Fig. 6f and g with b). Perhaps the individual inhibitors were
more potent than GF alone and so were able to inhibit their
individual isoforms more completely than GF did. Treatment
with Hispidin, the PKCβ inhibitor, had no effect on growth or
differentiation, having the same morphology as was seen with
DMSO treatment (data not shown). In summary, inhibition of
either PKCα or δ had profound effects on raft morphology, but
blocking all of the PKCs with GF curiously had very little
effect.
To test whether the effects of our PKC isoform inhibitors on
the HPV life cycle in the differentiating environment of raftswas similar to those seen in MC culture, we extracted total DNA
from WT:1 raft cultures and assayed viral replication by
Southern analysis (Fig. 7a). It was apparent that treatment with
DMSO supported amplification to a high degree. Both Gö and
Rott were able to inhibit replication in these cultures relative to
their DMSO solvent control (Fig. 7a). p742 activity was also
enhanced slightly by treatment with DMSO, and only Rott-
treated rafts showed appreciable reduction of transcript levels
(Fig. 7b). Thus, the effects of these treatments on viral
transcription and replication were similar to those seen in
MC. Because raft cultures are able to support high levels of L1
transcript expression and PKC has been linked to L1 expression
in raft cultures (Hummel et al., 1995; Meyers et al., 1992), we
tested the effects of these PKC inhibitors on L1 transcript levels.
All three PKC inhibitors were able to reduce L1 transcript
levels, with GF and Rott being most effective (Fig. 7c).
Activation of PKC
In order to efficiently produce infectious virus particles in
raft cultures of 9E cells, addition of a PKC activator is necessary
(Meyers et al., 1992). The compound used in our laboratory for
Fig. 6. Morphology of 9E rafts treated with signaling inhibitors. 9E raft cultures were constructed and treated for 10 days with E medium (a), GF (b), 0.05% ethanol (c),
C8 (d), 0.05% DMSO (e), Gö (f), or Rott (g). GF, Rott, and Gö were at 5 μM, and C8 was at 10 μM. Paraffin-imbedded rafts were sectioned and stained with
hematoxylin and eosin. Images are at 200× magnification.
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observed that addition of PKC activators does not lead to an
increase in p742 activity in raft cultures (Hummel et al., 1995),
but C8 treatment does increase expression of L1 and L2
transcripts in raft cultures (Ozbun and Meyers, 1997, 1998a).
Whether C8 can have an effect on replication or on p742
activity in a short-term differentiation assay in MC has not been
reported. Given the observations above that PKC is necessary
for amplification, we sought to test whether PKC activation by
C8 would be sufficient to induce or enhance amplification in
MC. C8 had no obvious effects on growth or morphology of
cells in monolayer culture after 48 h of treatment (not shown).
When WT:1 cells, which were apparently more sensitive to
manipulation of PKC than 9E cells, were treated with C8,
ethanol vehicle, or GF, we found that C8 was not sufficient to
induce amplification in monolayer or enhancing amplification
in MC (Fig. 8a). (The modest increase in copy number inmonolayer by treatment with GF in this experiment was not
consistently seen.) C8 did not super-induce expression of L1
and L2 transcripts in monolayer or MC (Fig. 8b), indicating that
the features of raft cultures that allow enhancement of late
transcript expression by C8 are not mimicked in MC. From
these experiments, we conclude that PKC activation by C8 is
not sufficient to induce either intermediate or late events in
monolayer or MC.
Tyrosine kinases
We also wished to explore the contribution of other
signaling pathways in addition to PKC. Several tyrosine
phosphorylation events have been implicated in the control of
differentiation, some of which are upstream or downstream of
PKC (Cabodi et al., 2000; Calautti et al., 1995; Filvaroff et
al., 1990). Genistein (Gen) is a tyrosine kinase inhibitor and
Fig. 7. Effects of C8 and PKC inhibitors on HPV in raft culture. (a) Southern analysis of total DNA extracted from WT:1 rafts treated for 10 days with the indicated
compounds (GF, Rott, and Gö at 5 μM; C8 at 10 μM). Total RNAs from rafts treated as in part (a) were analyzed by RPA using (b) a probe against p742 or (c) a mixture
of probes against L1 and L2. A probe against cyclophilin was included as an internal control. B, digested with BamHI, which does not cut the HPV31 genome; H,
digested with HindIII which digests the HPV31 genome once; Y+, yeast RNA with RNAse treatment; Y−, yeast RNA without RNAse treatment.
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confluency, or TPA (Efimova et al., 1998; Filvaroff et al.,
1990; Paramio and Jorcano, 1997). We tested the efficacy of
Gen in inhibiting HPV amplification and p742 activation. As
seen in Fig. 5a, Gen was as effective in inhibiting
amplification as were the PKC inhibitors. It had no effect at
all on p742 activation or intermediate transcript expression,
however, as seen in Figs. 5b and c. This result indicates that
amplification depends on tyrosine phosphorylation but p742
activation does not and shows again that amplification and
p742 activation are controlled by distinguishable signaling
pathways.
Discussion
Several conclusions can be drawn from the results presented
here. First, PKC is clearly needed for the intermediate phase of
the viral life cycle. According to our data, a component ofp742 activation requires PKCδ, but viral genome amplification
depends on both PKCα and δ activity as well tyrosine kinases.
These observations will provide a starting point for untangling
the upstream signals and downstream factors used by the virus
to regulate each of these differentiation-dependent life cycle
events. Second, treatment with GF, Gö, and Gen differentially
affected replication and p742. In support of previous results
(Bodily and Meyers, 2005), these data form a strong body of
evidence that p742 activation and replication are separable
biochemically, and that late promoter activation does not
depend on increased viral copy number. That we have been
able to block amplification without blocking p742 and not vice
versa may suggest that p742 activation itself contributes to
amplification. Since the E1, E2, E4, and E5 genes are all
immediately downstream of p742 and all are implicated in
amplification (Fehrmann et al., 2003; Genther et al., 2003;
Ozbun and Meyers, 1998a; Peh et al., 2004; Stubenrauch et al.,
1998, 2000; Wilson et al., 2005), this seems a likely
Fig. 8. The effect of C8 on replication and L1/L2 expression. WT:1 cells were
incubated in monolayer or MC culture with 5 μM GF, 10 μM C8, or 0.05%
ethanol vehicle for 2 days. (a) Southern analysis of total DNAs. B, digested with
BamHI, which does not cut the HPV31 genome; H, digested with HindIII which
digests the HPV31 genome once. (b) RPA analyses on total RNAs were
performed using a mixture of probes against L2 and L1. A probe against
cyclophilin was included as an internal control. EtOH, ethanol; Y+, yeast RNA
with RNAse treatment; Y−, yeast RNA without RNAse treatment.
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inhibition of p742 does not necessarily result in inhibition of
the E1, E2, and E4 transcripts. This was an unexpected finding
and may indicate that the viral promoters are coordinately
regulated to ensure proper expression of viral transcripts at the
proper life cycle stage. Fourth, amplification appears to be
more susceptible to manipulation than p742 activation. Indeed,
only in a few cases have we observed p742 activation to be
inhibited (GF, Rott), and that was not always complete or
consistent from experiment to experiment. We infer that
amplification requires or responds to a greater variety of input
signals, or in other words, a more specific signaling envi-
ronment, than does p742 activation.
It is not clear from studies by others of overexpression or
inhibition of various PKC isoforms exactly what spectrum of
differentiation markers each can regulate or at exactly at which
stage of differentiation each operates. The PKC pathway has
been best studied at the spinous-to-granular transition rather
than at the basal-to-spinous transition where viral intermediate
events including amplification and p742 activation occur
(Ozbun and Meyers, 1997, 1998a; Flores and Lambert, 1997;
Ruesch et al., 1998). Given the general inhibitory effects of Rott
on amplification, p742 activation, and intermediate/late tran-script expression (Fig. 4), it appears that PKCδ has a necessary
function in the intermediate and late stages of the viral life cycle.
PKCδ in some studies has appeared to favor the expression of
both spinous and granular markers, while PKCα has been found
to inhibit spinous markers in favor of granular ones (Denning et
al., 1995a). Whether this is true only for the markers studied or
in all models of differentiation is not known. Published studies
using these inhibitors have generally used calcium- or
suspension-induced differentiation as model systems, so the
effects of PKC isoforms on the development of whole tissues
are not well understood. We are not aware of any previous
reports of these compounds being used in organotypic cultures.
It is possible that the response of keratinocytes to these drugs
may be different in a chronically treated, fully stratified
epithelium than in a less structured cell environment and a
shorter treatment regime as in MC culture or during calcium-
induced differentiation.
Interestingly, DMSO alone was able to increase both
amplification and p742 transcript levels in treated rafts. The
basis for this effect is not known but may relate to DMSO's
antioxidant activity (Macdonald et al., 2003), which could be
accentuated by the fact that raft cultures are exposed to air. It is
noteworthy that viral replication and transcript levels in the
small amount of material harvested from Gö treated rafts were
still comparable to that seen in C8 treated cultures, despite
Gö's dramatic inhibitory effect on raft tissue growth (see Fig.
6f). The basis of the fascinating vacuolization by Rott in raft
culture and inhibition of growth by Gö are not clear from
histology alone. The large holes in Rott-treated tissue could
relate to the known pro-apoptotic function of PKCδ (Denning
et al., 1998; Li et al., 1999), so that inhibition of this enzyme
may disrupt normal cell death in the tissue. It will be important
to further investigate whether and how these compounds affect
the expression of differentiation-specific marker proteins. It
may be, for example, that the failure of Gö-treated rafts to
develop may have been due, not to toxicity, but to the removal
of the inhibitory effect of PKCα on the basal-to-spinous
transition (Dlugosz and Yuspa, 1993), thereby forcing all of the
cells to differentiate at once, leaving no basal layer to
regenerate the tissue. This would explain how viral copy
number and p742 transcription could still be fairly robust even
in the face of Gö's dramatic effect on tissue growth. The data
in Fig. 7c are consistent with the possibility that L1 and L2
expressions require PKCδ activity, although whether this is
because p742 depends on PKCδ, or whether there are post-
transcriptional mechanisms employing PKC (Hummel et al.,
1995) remains to be determined.
Given that p99 has been reported to depend heavily on the
activity of AP-1 (Kyo et al., 1997), we would have expected p99
to be inhibited by GF rather than activated as we observed (Fig.
4c). This unexpected finding deserves further investigation.
Also interesting is that in the same samples that showed reduced
p742 activation, the intermediate transcripts (E1/2/4) were not
downregulated by GF (Fig. 4a vs. b). This result is provocative
for two reasons. First, it means that GF does not inhibit
amplification through inhibition of intermediate transcripts,
although whether the actual proteins are made at the same levels
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p742 activation is not necessarily the only factor underlying
upregulation of the intermediate transcripts during differentia-
tion, as we have assumed. It is known that p99 can contribute to
the pool of E1 and E2 transcripts (Ozbun and Meyers, 1997,
1998a). Perhaps activation of p99 observed in Fig. 4c is
sufficient to offset inhibition of p742 so that intermediate
transcript levels are kept constant. That there may be cross-
regulatory or feedback mechanisms in place between the
promoters is interesting and remains to be investigated.
Regulation of the intermediate phase of the life cycle may
thus be somewhat more complicated than simply increasing the
activity of p742.
The molecular mechanisms by which PKC affects ampli-
fication and late promoter activity remain to be worked out.
Specifically, we do not know the relevant upstream signals that
feed into the PKC pathway or the downstream targets that
impinge on the virus. It is known that E1 and E2 are
phosphorylated (Lentz et al., 2002; Ma et al., 1999; McBride
et al., 1989), but the functional consequences for the viral life
cycle are unknown. It would be attractive to suppose that PKC
could directly modify E1, thereby triggering the switch from
maintenance replication to amplification. Additional signaling
pathways could also be examined for their effects on HPV
intermediate and late activities. It is not clear from the
literature exactly which signals and factors are responsible for
the earliest steps of the differentiation pathway, but Notch and
c-Myc may be candidate factors at this stage (Gandarillas and
Watt, 1997; Lefort and Dotto, 2004) and may also have a
direct impact on p742. There is a possible binding site in the
p742 region for RBP-Jκ, a Notch-responsive transcription
factor, so further studies of Notch signaling in particular are
warranted. We have preliminary data that inhibition of the
MAPK pathways (JNK, MEK, and p38) has no significant
effect on HPV intermediate events (J.M.B and C.M.,
unpublished observations). It is possible that redundancy
between pathways could mask individual contributions. For
that reason, investigation of Ras, a major node upstream of all
of these pathways may be helpful, perhaps using a dominant
negative strategy. Although there is evidence that contracep-
tive hormones are risk factors in cancer progression (Brom-
berg-White and Meyers, 2003), the effects of hormones on
HPV gene expression and replication are not clear. Reporters
of the HPV18 URR can be activated by dexamethasone, but
HPV31 URR reporters are activated to a much lesser degree
and only under differentiating conditions (Bromberg-White
and Meyers, 2002; Bromberg-White et al., 2003); studies on
late promoters and whole genomes are lacking. The effects of
physiological hormones, such as progesterone, estrogen, and
androgens on the HPV life cycle have not been extensively
investigated. Many other pathways or signals may also prove
fruitful for further study, including retinoids, 1,25 dihydroxy-
vitamin D, PPAR agonists or antagonists, KGF, TGF-β, JAK/
STAT, NFκB, cyclin/CDKs, calmodulin kinase, caspase
cascades, phosphatases, cholesterol sulfate and other lipid
mediators, focal adhesion or desmosomal signals, and many
others.Materials and methods
Compounds
GF109203X.HCl (GF), Genistein (Gen), and Gö6976 (Gö),
were obtained from Alexis Biochemicals. Hispidin was
obtained from EMD Biosciences. Rottlerin (Rott) and SN-1,2-
dioctanoylglycerol (C8) were obtained from Sigma. DMSO was
the solvent for Gen, Gö, Rott, and Hispdin. C8 was dissolved in
100% ethanol, and GF was dissolved in water. Generally, the
solvent was added directly to the shipping vial, and the
suspension was agitated to dissolve the drug. All drugs were
stored at −20 °C in small aliquots in sterile, amber
microcentrifuge tubes.
Cell culture
CIN-612 9E (9E) and HFK31a:1 (WT:1) cells were
maintained using standard cell culture techniques as described
(Bodily and Meyers, 2005; McLaughlin-Drubin et al., 2003;
Sen et al., 2002). Cells to be treated with drugs were plated
overnight at a density of 1–2 × 106cells/100 mm plate. The
next day, cells were trypsinized, resuspended, and cultured
either in monolayer at 1 × 106 cells/100 mm plate or
suspended at 1 × 106 cells/10 ml 1.6% methylcellulose (MC)
to induce differentiation. Each drug was added to the final
medium (monolayer or MC) before the addition of cells. Note
that in this scheme, cells cultured in monolayer were exposed
to the drug during attachment. The amount of drug needed for
a 10 ml culture was usually diluted in 0.5 ml E medium before
mixing with 10 ml E medium containing MC, thereby
facilitating even distribution of the drug throughout the
medium and precluding precipitation. Following 2 days of
culture, cells were harvested by washing (MC) or by treatment
with trypsin (monolayer), and the samples were divided for
either DNA or RNA analysis. Organotypic raft cultures were
prepared as described previously by construction of a collagen
matrix containing fibroblasts, seeding with keratinocytes, and
lifting to the air–liquid interface (Meyers, 1996; Meyers and
Laimins, 1994). Drugs were added at every feeding to the
medium used to feed the rafts, and the standard culture time
was 10 days.
Construction of HPV promoter reporter plasmids, including
pGL2B-1706 (fragment A), pGL2B-630 (fragment H), and
pGL2B-330Δ180 (fragment T), was described previously
(Bodily and Meyers, 2005). Transfection followed by differen-
tiation by suspension MC was performed as reported previously
(Bodily and Meyers, 2005; McLaughlin-Drubin et al., 2003;
Sen et al., 2002), except that cells were plated directly in KGM
overnight before transfection. GF (5 μM) was added to the
medium following transfection, and lysates were measured for
luciferase activity as described (Bromberg-White et al., 2003).
Southern and ribonuclease protection analysis
Southern blotting and ribonuclease protection analysis were
performed on total DNA or RNA as described previously
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et al., 2002). The p742 and L1 riboprobe templates, pGem330
and pGOZ 31L1, have been described (Bodily and Meyers,
2005; Ozbun and Meyers, 1997). Other riboprobe templates
were cloned by PCR using pBSHPV31 as template:
pGem930Δ700, pGemE1RPA, pGemE2/4 RPA, and
pGemL2RPA for p99, E1, E2/E4, and L2 riboprobe templates,
respectively. PCR primers introduced a KpnI site and a BglII site
into either end of the PCR products, and the digested products
were ligated into pGEM-7Zf(+) which had been digested with
KpnI and BamHI. pGem930Δ700 used primers CGCGA-
GATCTCTTTGCAGTAGACACAAT and CCGGGTACCA-
TAATTAATTGCATATAG. pGemE1 RPA used primers
CCGGGTACCCGGGGACGGGATGCAATGGTT and
GCGAGATCTGCATATAGCTTTTAACCGTG. pGemE2/4
RPA used primers CCGGGTACCGGGACTGGTAAAAAA-
TGGG and GCGAGATCTGTGGGTGTTTCTGTGCTCTG.
This riboprobe overlaps the ^E4 splice junction at HPV31
nucleotide 3295, resulting in two bands upon ribonuclease
digestion, one for E2 and one for ^E4. pGemL2 RPA used
primers CCGGGTACCGCCCCTGATCCCGACTTTCT and
GCGAGATCTGGCCCAGAAAATATGGGAAT. A probe
against cyclophilin was included in each hybridization as an
internal control (Steele et al., 2002).
Western blot analysis
For Western blots, whole cell extracts were prepared by
thawing cell pellets on ice and resuspending them in 250 μl
of buffer A (50 mM NaPO4 (pH 7.2), 5 mM EDTA, 50 mM
NaF, 0.5 μg/ml leupeptin, 0.5 μg/ml pepstatin, 20 μg/ml
aprotinin, 0.2 mM Na3VO4, 1 mM DTT, 1 mM PMSF). 250 μl
of buffer B was added (identical to Buffer A but
supplemented with 2% (w/v) SDS), and the samples were
boiled in a water bath for 8 min, vortexing briefly every 2
min. Samples were transferred into a 1.5 ml microcentrifuge
tube, and supernatants were collected after centrifugation for
5 min at room temperature. From each sample, a 500 μl
aliquot of the supernatant was removed and added to 125 μl
of 5× sample loading buffer (100 mM Tris, pH 8.0, 5 mM
EDTA, 10% (w/v) sucrose, 2% (w/v) SDS, 33 mM DTT,
and 0.1 mg/ml Pyronin Y). Protein concentrations were
determined using the Lowry method as previously published
(Meyers et al., 2001). Protein extracts were applied to
sodium-dodecyl sulfate (SDS)-polyacrylamide gel (acrylam-
ide/bisacrylamide ratio, 30:0.8). A 6% gel was used to detect
involucrin expression by loading 2.5 μg of total protein
per sample. Proteins were transferred to nitrocellulose mem-
brane (Protran, Schleicher and Schuell). Membranes were
incubated overnight with the anti-involucrin primary antibody
(Sigma (SY5)) used at 1:10,000 dilution. After being
washed, the blots were incubated with anti-rabbit or anti-
mouse horseradish peroxidase-linked secondary antibody
(Amersham Life Science) as per manufacturer's instructions.
The proteins were detected using enhanced chemilumines-
cence (ECL) method (Perkin Elmer) as per manufacturer's
instructions.Protein kinase Cα kinase assay
Protein extracts for the kinase assay were prepared by
resuspending cell pellets consisting of 2 × 106 GF-treated and
untreated cells were in 600 μl Buffer A (described above) and
adding 400 μg of ice-cold acid washed glass beads (0.45 mm,
Sigma). Samples were vortexed for 30 s and chilled on ice for
30 s. This cell breakage procedure was repeated a total of five
times. The microfuge tubes were placed on the rim of 13 × 100
mm precooled disposable glass tubes. An 18-gauge needle was
used to puncture holes through the lid and bottom of the
microfuge tube. The piggy-back microfuge tube and glass tube
combination was centrifuged to attain a speed of 2000 rpm. The
eluted samples were transferred into new 1.5-ml microfuge
tube, and supernatants were collected by centrifugation for 5
min at 4 °C. Protein concentrations were measured using the
Bradford assay (Bio-Rad).
Immunoprecipitation buffer consisted of 1% Triton X-100,
10 mM HEPES (pH 7.5), 2 mM EDTA, 50 mM NaF, 0.2 mM
Na3VO4, 2 mM DTT, 200 mM NaCl, 20 μg/ml aprotinin,
0.5 μg/ml pepstatin, 0.5 μg/ml leupeptin, 1 mM PMSF. For
each immunoprecipitation reaction, a total of between 150
and 200 μg of protein extract was used. The volume was
made up to 1 ml with immunoprecipitation buffer supplemented
with 2% non-fat dry milk. All samples were first precleared
using 1:5000 dilution of mouse anti-cytokeratin AE1/AE3
monoclonal antibody (Chemicon International) by incubating
for 1 h at 4 °C with rotation. To each sample, 50 μl of
preswollen Protein A Sepharose beads (Amersham Bios-
ciences) were added and incubated at 4 °C for 30 min with
rotation. Beads were removed by centrifugation at 13,000 rpm
for 20 s. The precleared lysates were then subjected to
immunoprecipitation using 5 μl of a monoclonal antibody
against PKCα (cat. #P16520, Transduction Laboratories). After
addition of antibody, all samples incubated at 4 °C for 1.5 h with
rotation, followed by addition of 50 μl of preswollen Protein A
Sepharose beads. Samples were further incubated at 4 °C for
1 h with rotation. Beads were pelleted by centrifugation at
13,000 rpm for 20 s and then washed once with 500 μl ice-cold
immunoprecipitation buffer without milk supplementation, and
then twice in kinase buffer (20 mM HEPES, pH 7.4, 100 μM
CaCl2, 10 mM MgCl2). PKCα kinase assay was performed as
previously reported (Jin et al., 2004). Briefly, beads bound to the
immunoprecipitated PKCα were suspended in 50 μl of kinase
buffer supplemented with 200 μg/ml Histone H-1, 100 μMATP,
100 μg/ml phosphatidylserine, 2 μCi of [γ-32P] ATP, and 0.03%
Triton X-100. The mixture was incubated for 30 min at 30 °C.
The reaction was stopped by addition of 2× SDS sample buffer
and boiling the samples for 5 min. The samples were separated
using 12% SDS-PAGE followed by autoradiography.
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